UnitedHealth Group: Weak Q2 earnings led to cautious price forecast near $358

Traders Union
All News
Financial News
UnitedHealth Group slips 0.94% today

Highlights

UnitedHealth Group (UNH) trades at $358.18, just above the MA-20 and MA-50 but well below the MA-200 at $392.32, signaling short-term bullish momentum amid longer-term weakness.
KPP Advisory Services LLC increased holdings in UNH as of October 23, 2025, despite mixed earnings—Q2 missed estimates and analysts predict a significant EPS decline in Q3 2025.
Technical signals are mixed, with MACD bullish but the ADX selling and oscillators neutral, projecting a low likelihood of price gains and a likely sideways range of $357.15–$361.55 in the next five days.

Portfolio flows rise as mixed earnings temper strong financials

Regulatory filings on October 23, 2025, showed that KPP Advisory Services LLC acquired additional shares of UNH. The company continues to display strong financials, including a market cap of $321 billion, a P/E of 15.4, and a beta of 0.47. Recent earnings have shown a mix of results, with Q2 earnings missing estimates and analysts forecasting a significant EPS decline for Q3 2025.

Bullish momentum faces resistance amid conflicting technical signals

The nearest dynamic support is the Ichimoku Kijun at $354.41. The MA-50 and Kijun both act as support, with MA-200 above serving as the next major upside barrier. Momentum signals are mixed. The daily MACD points to strong buying pressure, while the ADX indicates a mildly bearish undertone with its daily sell signal. RSI is moderately bullish at 56.69, but Stoch RSI and CCI remain neutral, showing no clear overbought or oversold signal. Bull/Bear Power is neutral, suggesting an even balance between buyers and sellers intraday. The Awesome Oscillator reinforces the cautious tone, confirming the prevailing bearish daily movement. The price opened with a slight downside gap from the previous close ($361.57 to $355.04), has recovered moderately, and now trades near the upper end of today’s range ($359.49 high, $353.69 low). Intraday volatility is moderate, with sellers showing pressure after the open. Divergence between strong bullish MACD and cautious-to-bearish ADX, oscillators, and price action highlights ongoing uncertainty.

Downside risk increases as probability of near-term rebound falls

For the next five trading days, the projected price range is $357.15 to $361.55, with an average near $359.35. The probability of a price increase is very low (less than 20%), making a decrease more likely. In the baseline scenario, the stock is expected to remain in a narrow sideways range, holding near the current levels. A bullish scenario would require a move above $359.49, potentially targeting resistance from the MA-200, while a break below $354.41 support could trigger further losses, in line with weak weekly momentum signals.

Anton Kharitonov, analyst at Traders Union, sees UnitedHealth (UNH) as maintaining a precarious technical stance, with short- and medium-term support, but unable to reclaim critical long-term levels. He notes that despite recent institutional buying and robust fundamentals, weak earnings momentum and mixed technical indicators point to continued uncertainty rather than upside conviction. The probability of near-term gains remains low, setting the baseline expectation of sideways or lower price action. "As long as UNH remains beneath the $392.32 MA-200 and momentum fails to improve, I find little reason to trust a sustained recovery—risk remains firmly to the downside."

Previously it was noted that bullish momentum diverges from overbought signals amid increased volatility in UNH shares. At that time, investors were relying on technical signals due to muted news flow and ongoing market uncertainty, as described in the discussion about bullish momentum diverges from overbought signals.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.